Completed

Pyrimethamine and Clindamycin vs. Pyrimethamine and Sulfonamides for Toxoplasmic Encephalitis in AIDS Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Pyrimethamine

+ Clindamycin

Drug
Who is being recruted

Abscess+31

+ Blood-Borne Infections

+ Neuroinflammatory Diseases

Over 18 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorPalo Alto Medical Foundation
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on treating a condition called Toxoplasmic Encephalitis, a brain infection caused by the parasite Toxoplasma gondii, in patients who also have AIDS. The main aim is to compare the effectiveness of two different treatment combinations. One combination involves the use of a drug called pyrimethamine along with intravenous (IV) clindamycin, while the other combines pyrimethamine with sulfonamides. The study targets individuals living with AIDS who have this specific brain infection. The importance of this research lies in finding a more effective treatment approach to manage this serious condition and improve the quality of life for those affected.

Principal SponsorPalo Alto Medical Foundation
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AbscessBlood-Borne InfectionsNeuroinflammatory DiseasesUrogenital DiseasesGenital DiseasesBrain AbscessBrain DiseasesCentral Nervous System DiseasesCentral Nervous System InfectionsCoccidiosisCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsNervous System DiseasesOpportunistic InfectionsParasitic DiseasesProtozoan InfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesSuppurationVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsCentral Nervous System Parasitic InfectionsCentral Nervous System Protozoal InfectionsAcquired Immunodeficiency SyndromeEncephalitisToxoplasmosisHIV InfectionsToxoplasmosis, CerebralAIDS-Related Opportunistic Infections

Criteria

3 exclusion criteria prevent from participating
Patients with AIDS and cerebral toxoplasmosis

Patients with opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy

Patients with other opportunistic infections or brain diseases

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Palo Alto Med Foundation

Palo Alto, United StatesOpen Palo Alto Med Foundation in Google Maps
CompletedOne Study Center